Versartis, Inc. (VSAR) Shares Bought by Geode Capital Management LLC
Geode Capital Management LLC raised its stake in Versartis, Inc. (NASDAQ:VSAR) by 41.0% during the first quarter, Holdings Channel reports. The institutional investor owned 257,417 shares of the biopharmaceutical company’s stock after buying an additional 74,865 shares during the period. Geode Capital Management LLC’s holdings in Versartis were worth $5,495,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of VSAR. Russell Investments Group Ltd. acquired a new position in Versartis during the fourth quarter valued at $116,000. American International Group Inc. boosted its position in Versartis by 20.7% in the first quarter. American International Group Inc. now owns 18,962 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 3,250 shares in the last quarter. Wellington Management Group LLP acquired a new position in Versartis during the first quarter valued at $408,000. Cornerstone Capital Management Holdings LLC. acquired a new position in Versartis during the first quarter valued at $463,000. Finally, Metropolitan Life Insurance Co. NY boosted its position in Versartis by 22.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 23,257 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 4,270 shares in the last quarter. 77.88% of the stock is owned by institutional investors and hedge funds.
Shares of Versartis, Inc. (NASDAQ:VSAR) traded up 1.51% during trading on Friday, reaching $16.80. The company had a trading volume of 66,202 shares. The company’s market cap is $597.71 million. The firm has a 50 day moving average price of $17.84 and a 200 day moving average price of $17.95. Versartis, Inc. has a 12 month low of $9.05 and a 12 month high of $24.00.
Versartis (NASDAQ:VSAR) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.20. Analysts predict that Versartis, Inc. will post ($3.29) earnings per share for the current year.
Several equities analysts recently issued reports on the company. Zacks Investment Research lowered Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. BidaskClub lowered Versartis from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Canaccord Genuity set a $28.00 price target on Versartis and gave the company a “buy” rating in a research note on Sunday, May 28th. Piper Jaffray Companies set a $26.00 price target on Versartis and gave the company a “buy” rating in a research note on Tuesday, June 27th. Finally, Cantor Fitzgerald set a $34.00 price target on Versartis and gave the company a “buy” rating in a research note on Thursday, July 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Versartis currently has a consensus rating of “Buy” and a consensus target price of $25.13.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis, Inc. (NASDAQ:VSAR).
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.